Notice: This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends Get the Latest News and Ratings for BOLD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Audentes Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up BOLD Analyst Ratings Over TimeTypeCurrent Forecast12/26/23 to 12/25/241 Month Ago11/26/23 to 11/25/243 Months Ago9/27/23 to 9/26/241 Year Ago12/26/22 to 12/26/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s) N/A Buy2 Buy rating(s)3 Buy rating(s)3 Buy rating(s) N/A Hold1 Hold rating(s)0 Hold rating(s)0 Hold rating(s) N/A Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s) N/A Consensus Price Target$23.00$23.00$23.00N/AForecasted Upside791.47% Upside798.44% Upside553.41% UpsideN/AConsensus RatingModerate BuyBuyBuyN/A Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. BOLD Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BOLD Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Audentes Therapeutics Stock vs. The CompetitionTypeAudentes TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.67 2.81 2.51Consensus RatingModerate BuyModerate BuyModerate BuyPredicted Upside791.47% Upside26,167.05% Upside13.49% UpsideNews Sentiment RatingNeutral NewsSee Recent BOLD NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails12/13/2024Guggenheim2 of 5 starsM. SchmidtSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/22/2024Piper Sandler2 of 5 stars Initiated CoverageOverweight$20.00+98.22%4/22/2024Leerink Partners1 of 5 stars Initiated CoverageOutperform$25.00+147.77%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:06 PM ET. BOLD Forecast - Frequently Asked Questions What is Audentes Therapeutics' forecast for 2025? According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Audentes Therapeutics is $23.00, with a high forecast of $25.00 and a low forecast of $20.00. Should I buy or sell Audentes Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last twelve months. There is currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BOLD shares. Does Audentes Therapeutics's stock price have much upside? According to analysts, Audentes Therapeutics's stock has a predicted upside of 791.47% based on their 12-month stock forecasts. Has Audentes Therapeutics been downgraded by Wall Street analysts recently? Over the previous 90 days, Audentes Therapeutics's stock had 1 downgrade by analysts. What analysts cover Audentes Therapeutics? Audentes Therapeutics has been rated by research analysts at Guggenheim in the past 90 days. Do Wall Street analysts like Audentes Therapeutics more than its competitors? Analysts like Audentes Therapeutics less than other "medical" companies. The consensus rating score for Audentes Therapeutics is 2.67 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BOLD compares to other companies. Stock Forecasts and Research Tools Related Companies DiaMedica Therapeutics Stock Forecast Zentalis Pharmaceuticals Stock Forecast Precigen Stock Forecast ProQR Therapeutics Stock Forecast Aclaris Therapeutics Stock Forecast LifeVantage Stock Forecast Lexicon Pharmaceuticals Stock Forecast Silence Therapeutics Stock Forecast MacroGenics Stock Forecast Atai Life Sciences Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem This page (NASDAQ:BOLD) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLD Stock Alerts